Flavocoxid
Common name
N/A
ID
HD0027
Scientific name of the plant
N/A
Anatomical part for use
N/A
Human use
Pain and inflammation
Summary
Flavocoxid is a medical food consisting of plant derived flavonoids which have anti-inflammatory activity and are used to provide nutritional support to people with chronic osteoarthritis.Flavocoxid has been approved for use as a medical food in the United States since 2004 and is available by prescription for use in chronic osteoarthritis in tablets of 500 mg under the commercial name Limbrel.Flavocoxid has been linked to occasional minor elevations in serum enzyme levels during therapy and to rare instances of clinically apparent liver injury. (Source: Wiki)
Evidence Level
Level 1 (Individual reports from one medical center)
Hepatotoxicity reports in literature
- Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series : (Source)
Hepatotoxicity Description
In premarketing clinical trials, serum aminotransferase elevations occurred in up to 10% of patients on flavocoxid therapy, but elevations above 3 times the upper limit of normal occurred in only 1% to 2% of recipients. Since its release, however, there have been several reports of clinically apparent acute liver injury attributed to flavocoxid. Most cases have occurred in women, who perhaps are more likely to use flavocoxid. The time to onset was 1 to 5 months, and the pattern of enzyme elevations was usually hepatocellular or mixed. Most cases were moderate in severity and no instance of acute liver failure or death has been reported. Resolution upon stopping flavocoxid occurred in 1 to 3 months. Immunoallergic features were present in some patients, but were mild and autoantibodies were not common. At least one instance of recurrence upon rechallenge has been reported. (Source: LiverTox)
Common name
N/A
ID
HD0027
Scientific name of the plant
N/A
Anatomical part for use
N/A
Human use
Pain and inflammation
Summary
Flavocoxid is a medical food consisting of plant derived flavonoids which have anti-inflammatory activity and are used to provide nutritional support to people with chronic osteoarthritis.Flavocoxid has been approved for use as a medical food in the United States since 2004 and is available by prescription for use in chronic osteoarthritis in tablets of 500 mg under the commercial name Limbrel.Flavocoxid has been linked to occasional minor elevations in serum enzyme levels during therapy and to rare instances of clinically apparent liver injury. (Source: Wiki)
Evidence Level
Level 1 (Individual reports from one medical center)
Hepatotoxicity reports in literature
- Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series : (Source)
Hepatotoxicity Description
In premarketing clinical trials, serum aminotransferase elevations occurred in up to 10% of patients on flavocoxid therapy, but elevations above 3 times the upper limit of normal occurred in only 1% to 2% of recipients. Since its release, however, there have been several reports of clinically apparent acute liver injury attributed to flavocoxid. Most cases have occurred in women, who perhaps are more likely to use flavocoxid. The time to onset was 1 to 5 months, and the pattern of enzyme elevations was usually hepatocellular or mixed. Most cases were moderate in severity and no instance of acute liver failure or death has been reported. Resolution upon stopping flavocoxid occurred in 1 to 3 months. Immunoallergic features were present in some patients, but were mild and autoantibodies were not common. At least one instance of recurrence upon rechallenge has been reported. (Source: LiverTox)